JP2019513373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513373A5 JP2019513373A5 JP2018551996A JP2018551996A JP2019513373A5 JP 2019513373 A5 JP2019513373 A5 JP 2019513373A5 JP 2018551996 A JP2018551996 A JP 2018551996A JP 2018551996 A JP2018551996 A JP 2018551996A JP 2019513373 A5 JP2019513373 A5 JP 2019513373A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- pharmaceutical composition
- tumor
- hla
- encoded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022088325A JP7491965B2 (ja) | 2016-03-31 | 2022-05-31 | ネオ抗原およびその使用方法 |
| JP2024080050A JP2024105596A (ja) | 2016-03-31 | 2024-05-16 | ネオ抗原およびその使用方法 |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662316530P | 2016-03-31 | 2016-03-31 | |
| US201662316552P | 2016-03-31 | 2016-03-31 | |
| US201662316547P | 2016-03-31 | 2016-03-31 | |
| US201662316533P | 2016-03-31 | 2016-03-31 | |
| US62/316,547 | 2016-03-31 | ||
| US62/316,552 | 2016-03-31 | ||
| US62/316,530 | 2016-03-31 | ||
| US62/316,533 | 2016-03-31 | ||
| US201662316567P | 2016-04-01 | 2016-04-01 | |
| US201662316571P | 2016-04-01 | 2016-04-01 | |
| US62/316,571 | 2016-04-01 | ||
| US62/316,567 | 2016-04-01 | ||
| PCT/US2017/025462 WO2017173321A1 (en) | 2016-03-31 | 2017-03-31 | Neoantigens and methods of their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022088325A Division JP7491965B2 (ja) | 2016-03-31 | 2022-05-31 | ネオ抗原およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019513373A JP2019513373A (ja) | 2019-05-30 |
| JP2019513373A5 true JP2019513373A5 (enExample) | 2020-05-07 |
Family
ID=59966480
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551996A Withdrawn JP2019513373A (ja) | 2016-03-31 | 2017-03-31 | ネオ抗原およびその使用方法 |
| JP2022088325A Active JP7491965B2 (ja) | 2016-03-31 | 2022-05-31 | ネオ抗原およびその使用方法 |
| JP2024080050A Pending JP2024105596A (ja) | 2016-03-31 | 2024-05-16 | ネオ抗原およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022088325A Active JP7491965B2 (ja) | 2016-03-31 | 2022-05-31 | ネオ抗原およびその使用方法 |
| JP2024080050A Pending JP2024105596A (ja) | 2016-03-31 | 2024-05-16 | ネオ抗原およびその使用方法 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20190307868A1 (enExample) |
| EP (1) | EP3436048B1 (enExample) |
| JP (3) | JP2019513373A (enExample) |
| KR (2) | KR20180129899A (enExample) |
| CN (2) | CN109310739A (enExample) |
| AU (4) | AU2017240745B2 (enExample) |
| BR (1) | BR112018070183A2 (enExample) |
| CA (1) | CA3018748A1 (enExample) |
| CO (1) | CO2018011668A2 (enExample) |
| CR (1) | CR20180519A (enExample) |
| DK (1) | DK3436048T3 (enExample) |
| EC (1) | ECSP18082207A (enExample) |
| ES (1) | ES3036912T3 (enExample) |
| FI (1) | FI3436048T3 (enExample) |
| HR (1) | HRP20251095T1 (enExample) |
| HU (1) | HUE072805T2 (enExample) |
| IL (4) | IL299926B2 (enExample) |
| LT (1) | LT3436048T (enExample) |
| MA (1) | MA44524A (enExample) |
| MX (1) | MX2023001403A (enExample) |
| PE (1) | PE20181923A1 (enExample) |
| PH (1) | PH12018502047A1 (enExample) |
| PL (1) | PL3436048T3 (enExample) |
| PT (1) | PT3436048T (enExample) |
| RS (1) | RS67172B1 (enExample) |
| SG (1) | SG11201808196UA (enExample) |
| SI (1) | SI3436048T1 (enExample) |
| TW (3) | TWI781928B (enExample) |
| WO (1) | WO2017173321A1 (enExample) |
Families Citing this family (133)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| JP7060324B2 (ja) | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| EP3234130B1 (en) | 2014-12-19 | 2020-11-25 | The Broad Institute, Inc. | Methods for profiling the t-cell- receptor repertoire |
| JP6913032B2 (ja) | 2015-05-20 | 2021-08-04 | ザ・ブロード・インスティテュート・インコーポレイテッド | 共通ネオ抗原 |
| JP2019505512A (ja) | 2016-01-08 | 2019-02-28 | バッシボディ アクスイェ セルスカプ | 治療用抗癌ネオエピトープワクチン |
| SG11201808196UA (en) * | 2016-03-31 | 2018-10-30 | Neon Therapeutics Inc | Neoantigens and methods of their use |
| WO2017177207A1 (en) | 2016-04-07 | 2017-10-12 | Bostongene, Llc | Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines |
| EP3574116A1 (en) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| WO2018148381A1 (en) * | 2017-02-07 | 2018-08-16 | Nantcell, Inc. | Maximizing t-cell memory and compositions and methods therefor |
| EP3606550A2 (en) | 2017-04-03 | 2020-02-12 | Neon Therapeutics, Inc. | Protein antigens and uses thereof |
| JP2020515629A (ja) | 2017-04-04 | 2020-05-28 | アヴィディア テクノロジーズ， インコーポレイテッド | 免疫応答を誘導するためのペプチドベースのワクチン、それらの製造方法および使用 |
| KR102945203B1 (ko) | 2017-05-08 | 2026-03-31 | 시애틀 프로젝트 코포레이션 | 알파바이러스 신생항원 벡터 |
| CN107188956A (zh) * | 2017-07-06 | 2017-09-22 | 江苏迈健生物科技发展股份有限公司 | 抗原肽t790m‑4及其在制备治疗非小细胞肺癌的药物中的应用 |
| CN107188957A (zh) * | 2017-07-06 | 2017-09-22 | 江苏迈健生物科技发展股份有限公司 | 抗原肽t790m‑1及其在制备治疗非小细胞肺癌的药物中的应用 |
| CN107325172A (zh) * | 2017-07-06 | 2017-11-07 | 江苏迈健生物科技发展股份有限公司 | 抗原肽t790m‑2及其在制备治疗非小细胞肺癌的药物中的应用 |
| WO2019051127A1 (en) | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
| US12025615B2 (en) | 2017-09-15 | 2024-07-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of classifying response to immunotherapy for cancer |
| WO2019084538A1 (en) * | 2017-10-27 | 2019-05-02 | Board Of Regents, The University Of Texas System | TUMOR SPECIFIC ANTIBODIES, T CELL RECEPTORS AND METHODS OF IDENTIFICATION THEREOF |
| CA3080835A1 (en) | 2017-10-31 | 2019-05-09 | Pantarhei Bioscience B.V. | Immunotherapeutic methods for treating and/or preventing lung cancer |
| WO2019094396A1 (en) * | 2017-11-07 | 2019-05-16 | Nektar Therapeutics | Immunotherapeutic combination for treating cancer |
| MX2020005454A (es) | 2017-11-27 | 2020-08-27 | Ose Immunotherapeutics | Tratamiento de cancer mejorado. |
| AU2018386331B2 (en) | 2017-12-15 | 2025-04-10 | Baylor College Of Medicine | Methods and compositions for the amplification of mRNA |
| TW201930340A (zh) * | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| WO2019140278A1 (en) * | 2018-01-11 | 2019-07-18 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting core binding factor antigens |
| US11573230B2 (en) * | 2018-01-26 | 2023-02-07 | Nantcell, Inc. | Rapid verification of virus particle production for a personalized vaccine |
| CN108384846B (zh) * | 2018-02-28 | 2020-06-16 | 固安博健生物技术有限公司 | C11orf95基因及其表达产物在诊治类风湿性关节炎和骨关节炎方面的应用 |
| WO2019183036A1 (en) * | 2018-03-19 | 2019-09-26 | Innovate Biopharmaceuticals, Inc. | Compositions and methods for potentiating immune checkpoint inhibitor therapy |
| WO2019217837A1 (en) | 2018-05-11 | 2019-11-14 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting pik3ca mutations and uses thereof |
| TW202000907A (zh) * | 2018-05-23 | 2020-01-01 | 美商葛利史東腫瘤科技公司 | 共有抗原 |
| WO2019237385A1 (zh) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | 用于敲除人TNFSF9基因的gRNA序列及其应用 |
| SG11202012653XA (en) * | 2018-06-19 | 2021-01-28 | Biontech Us Inc | Neoantigens and uses thereof |
| KR20210040355A (ko) * | 2018-06-19 | 2021-04-13 | 바이오엔테크 유에스 인크. | 네오항원 및 이의 용도 |
| CA3106980A1 (en) * | 2018-07-22 | 2020-01-30 | Health Research, Inc. | Major histocompatibility complex class ll-expressing cancer cell vaccine and methods of use for producing integrated immune responses |
| WO2020023361A1 (en) * | 2018-07-23 | 2020-01-30 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Enhancing anti-tumor response in melanoma cells with defective sting signaling |
| WO2020022901A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for uterine cancer |
| CA3106567A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for kidney cancer |
| WO2020022897A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database |
| CA3106573A1 (en) * | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for colorectal cancer |
| EP3827262A1 (en) | 2018-07-26 | 2021-06-02 | Frame Pharmaceuticals B.V. | Cancer vaccines for breast cancer |
| CA3106574A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Arid1a, cdkn2a, kmt2b, kmt2d, tp53 and pten vaccines for cancer |
| CN113164445A (zh) * | 2018-08-02 | 2021-07-23 | 得克萨斯系统大学评议会 | Tlr1/2激动剂地普罗考姆的佐剂作用协同增效检查点抑制性抗体以消除疾病 |
| AU2019321608B2 (en) | 2018-08-16 | 2024-07-25 | Biontech Us Inc. | T cell receptor constructs and uses thereof |
| US20210340201A1 (en) * | 2018-08-22 | 2021-11-04 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting kras or her2 antigens |
| US20210213121A1 (en) * | 2018-09-05 | 2021-07-15 | Vaximm Ag | Neoantigen targeting dna vaccine for combination therapy |
| EP3876971A4 (en) * | 2018-11-06 | 2023-01-11 | Icahn School of Medicine at Mount Sinai | PEPTIDES, COMPOSITIONS AND VACCINES FOR THE TREATMENT OF HYPERMUTATED TUMORS WITH MICROSATELLITE INSTABILITY AND METHODS OF USE THEREOF |
| KR20210090650A (ko) | 2018-11-07 | 2021-07-20 | 그릿스톤 바이오, 인코포레이티드 | 알파바이러스 신생항원 벡터 및 인터페론 억제제 |
| CN109438570B (zh) * | 2018-11-28 | 2021-07-20 | 生命谷（海南）生物科技股份有限公司 | 肿瘤相关基因fgfr3突变短肽及其应用 |
| WO2020121226A1 (en) * | 2018-12-12 | 2020-06-18 | Medimmune, Llc | Blood-based tumor mutation burden predicts overall survival in non-small cell lung cancer |
| JP2022512384A (ja) * | 2018-12-13 | 2022-02-03 | ロード アイランド ホスピタル | Ａｓｐｈ発現腫瘍の成長および進行の阻害 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020163876A1 (en) * | 2019-02-08 | 2020-08-13 | The Regents Of The University Of California | Compositions and methods involving layilin |
| CN119455003A (zh) | 2019-02-12 | 2025-02-18 | Ambrx公司 | 包含抗体-tlr激动剂缀合物的组合物、方法和用途 |
| GB2613715B (en) | 2019-02-20 | 2023-12-06 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
| US20220169746A1 (en) * | 2019-02-26 | 2022-06-02 | The University Of Vermont And State Agricultural College | Antibodies to neoantigens and uses thereof |
| CN113631185A (zh) * | 2019-02-27 | 2021-11-09 | 尼克塔治疗公司 | 用于治疗癌症的免疫治疗组合 |
| CA3131824A1 (en) * | 2019-03-11 | 2020-09-17 | Birgitte Rono | Nucleic acid vaccination using neo-epitope encoding constructs |
| WO2020186356A1 (en) * | 2019-03-20 | 2020-09-24 | Turnstone Biologics Inc. | Methods for inducing an immune response against neoantigens |
| US20220282217A1 (en) * | 2019-03-30 | 2022-09-08 | Biontech Us Inc. | Compositions and methods for preparing t cell compositions and uses thereof |
| CN111777677A (zh) * | 2019-04-04 | 2020-10-16 | 天津亨佳生物科技发展有限公司 | 一种egfr t790m 新抗原表位肽及其在治疗肿瘤中的应用 |
| MA55896A (fr) * | 2019-05-07 | 2022-03-16 | Modernatx Inc | Polynucléotides servant à perturber l'activité de cellule immunitaire et procédés pour les utiliser |
| TWI867324B (zh) | 2019-05-08 | 2024-12-21 | 美商百歐恩泰美國公司 | T細胞製備組合物及方法 |
| CN110201418B (zh) * | 2019-05-09 | 2020-10-27 | 西安交通大学 | 一种基于固定化SNAP-tag融合蛋白的细胞膜色谱柱及其制备方法 |
| SG11202113187WA (en) | 2019-05-30 | 2021-12-30 | Gritstone Bio Inc | Modified adenoviruses |
| DE102019114735A1 (de) * | 2019-06-02 | 2020-12-03 | PMCR GmbH | HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen |
| EP3982980A4 (en) * | 2019-06-12 | 2023-11-29 | BioNTech US Inc. | NEOANTIGEN COMPOSITIONS AND USES THEREOF |
| WO2021011417A1 (en) * | 2019-07-12 | 2021-01-21 | The Regents Of The University Of California | Chemically controlled monoclonal antibody target engagement |
| CN118638240A (zh) * | 2019-07-26 | 2024-09-13 | 柳韩洋行 | 抗her2/抗4-1bb双特异性抗体及其用途 |
| MX2022001027A (es) | 2019-07-26 | 2022-04-18 | Abl Bio Inc | Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo. |
| US20220265792A1 (en) * | 2019-07-30 | 2022-08-25 | Breakbio Corp. | Methods for treating solid tumors |
| EP4021934A4 (en) * | 2019-08-30 | 2024-02-14 | The Regents of the University of California | METHODOLOGIES FOR SCREENING FOR OVEREXPRESSION OF GENE FRAGMENTS AND RELATED USES |
| EP4038222A4 (en) | 2019-10-02 | 2023-10-18 | Arizona Board of Regents on behalf of Arizona State University | Methods and compositions for identifying neoantigens for use in treating and preventing cancer |
| EP4041293A1 (en) * | 2019-10-10 | 2022-08-17 | PACT Pharma, Inc. | Method of treating immunotherapy non-responders with an autologous cell therapy |
| EP4125973A4 (en) * | 2019-11-04 | 2024-03-13 | Gritstone bio, Inc. | NEOANTIGEN VACCINE THERAPY |
| US12570696B2 (en) | 2019-11-07 | 2026-03-10 | Shenzhen Gino Biotechnology Co., Ltd. | Tumor-specific polypeptide sequence and use thereof |
| CA3157411A1 (en) * | 2019-11-15 | 2021-05-20 | Karin Jooss | Antigen-binding proteins targeting shared neoantigens |
| EP4062178A1 (en) * | 2019-11-18 | 2022-09-28 | Epivax Therapeutics, Inc. | Improved neo-epitope vaccines and methods of treating cancer |
| KR102410556B1 (ko) * | 2020-01-16 | 2022-06-20 | 아주대학교산학협력단 | 미토콘드리아 타겟팅용 펩타이드 |
| KR102397922B1 (ko) * | 2020-02-19 | 2022-05-13 | 서울대학교 산학협력단 | 신규한 종양-관련 항원 단백질 olfm4 및 이의 용도 |
| KR102159921B1 (ko) * | 2020-03-24 | 2020-09-25 | 주식회사 테라젠바이오 | 펩타이드 서열 및 hla 대립유전자 서열을 이용하여 신생항원을 예측하는 방법 및 컴퓨터 프로그램 |
| WO2021205027A1 (en) | 2020-04-09 | 2021-10-14 | Vaccibody As | Individualized therapeutic anticancer vaccine |
| CN111729084B (zh) * | 2020-04-30 | 2021-05-11 | 南京北恒生物科技有限公司 | Sting激动剂与工程化免疫细胞的组合疗法 |
| US11130787B2 (en) * | 2020-06-11 | 2021-09-28 | MBF Therapeutics, Inc. | Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods |
| EP4165059A1 (en) * | 2020-06-13 | 2023-04-19 | Complete Omics Inc. | Method and system for neoantigen analysis |
| WO2021259963A1 (en) | 2020-06-23 | 2021-12-30 | Pandora Endocrine Innovation B.V. | Immunization against wnt4 for treatment and prophylaxis of breast cancer |
| WO2022009049A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| IL300026A (en) * | 2020-08-06 | 2023-03-01 | Gritstone Bio Inc | Multiepitope vaccine cassettes |
| CN112023062A (zh) * | 2020-09-18 | 2020-12-04 | 北京基因安科技有限公司 | 一个用可溶性IgE受体抑制过敏反应的方法 |
| EP4225358A4 (en) * | 2020-10-06 | 2025-09-17 | Univ California | PATTERNED NEO-EPITOPES FOR CANCER IMMUNOTHERAPY |
| KR20230086765A (ko) | 2020-10-13 | 2023-06-15 | 얀센 바이오테크 인코포레이티드 | 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법 |
| WO2022082030A2 (en) | 2020-10-15 | 2022-04-21 | Gritstone Bio, Inc. | Antigen-binding proteins and related methods of use |
| WO2022099157A1 (en) * | 2020-11-06 | 2022-05-12 | Cue Biopharma, Inc. | Antigen presenting polypeptide complexes and methods of use thereof |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| JP2023550148A (ja) | 2020-11-20 | 2023-11-30 | シンシア・イノベーション・インコーポレイテッド | がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法 |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| WO2022125504A1 (en) * | 2020-12-07 | 2022-06-16 | Iogenetics, Llc | Bystander protein vaccines |
| WO2022155503A1 (en) | 2021-01-14 | 2022-07-21 | Gritstone Bio, Inc. | Multi-specific antibodies and methods of use |
| WO2022165175A1 (en) * | 2021-01-28 | 2022-08-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Novel esr1 derived peptides and uses thereof for neoantigen therapy |
| CN117279658A (zh) * | 2021-02-09 | 2023-12-22 | 弗吉尼亚联邦大学 | 微小环状rna治疗剂和疫苗及其使用方法 |
| AU2022221309A1 (en) * | 2021-02-09 | 2023-08-24 | Virginia Commonwealth University | Mini circular rna therapeutics and vaccines and methods of use thereof |
| WO2022179568A1 (en) * | 2021-02-25 | 2022-09-01 | Westlake Therapeutics (Hangzhou) Co., Limited | Neoantigenic peptide and its use for treating braf gene mutation related diseases |
| CN113173985A (zh) * | 2021-03-24 | 2021-07-27 | 深圳市新靶向生物科技有限公司 | 一种与结直肠癌驱动基因突变相关的抗原肽及其应用 |
| JP2024516542A (ja) * | 2021-04-06 | 2024-04-16 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｍｈｃクラスｉペプチドを含む方法および組成物 |
| EP4326319A4 (en) * | 2021-04-22 | 2025-05-28 | Iogenetics, LLC. | Personalized allogeneic immunotherapy |
| US20240358808A1 (en) * | 2021-04-23 | 2024-10-31 | Flow Pharma, Inc. | Vaccine for sars-cov-2 |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| WO2022236073A1 (en) * | 2021-05-06 | 2022-11-10 | Astrin Biosciences Inc. | Trojan circulating tumor cells |
| AU2021461416A1 (en) | 2021-08-24 | 2024-02-22 | BioNTech SE | In vitro transcription technologies |
| WO2023059606A1 (en) * | 2021-10-06 | 2023-04-13 | Cancervax, Inc. | Methods and compositions for cancer treatment |
| WO2023060195A1 (en) * | 2021-10-08 | 2023-04-13 | Baylor College Of Medicine | Targeting common somatic mutations in breast cancer with neo-antigen specific adoptive t cell therapy |
| US20250026818A1 (en) | 2021-10-19 | 2025-01-23 | Sciencemed Spóka z ograniczon odpowiedzialnoci | Male contraception |
| CN114478712B (zh) * | 2022-03-29 | 2022-09-23 | 深圳吉诺因生物科技有限公司 | Hpv抗原表位及其鉴定方法、应用 |
| CN114605499B (zh) * | 2022-04-07 | 2023-06-23 | 华中科技大学同济医学院附属协和医院 | 一种可拮抗rbsm1蛋白rna结合活性的多肽rip-18及其应用 |
| EP4518886A4 (en) * | 2022-05-06 | 2026-05-06 | Childrens Medical Ct Corp | Vaccines against Anaplastic Lymphoma Kinase (ALK) Cancer and their methods of use |
| KR20240017325A (ko) * | 2022-07-29 | 2024-02-07 | 주식회사 엘지화학 | 항원 전달용 재조합 융합 단백질 및 이의 이용 |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| AU2023367780A1 (en) | 2022-10-25 | 2025-03-27 | Barinthus Biotherapeutics North America, Inc. | Self-assembling nanoparticles |
| US20260174837A1 (en) * | 2022-11-07 | 2026-06-25 | The Wistar Institute Of Anatomy And Biology | Compositions comprising neoantigens and methods of enhancing anti-pd1 therapy |
| EP4644410A4 (en) * | 2022-12-30 | 2026-07-01 | Lg Chemical Ltd | Recombinant fusion protein with a modified cysteine residue for antigen delivery and its uses |
| WO2024148181A2 (en) * | 2023-01-04 | 2024-07-11 | Board Of Regents, The University Of Texas System | T cell receptors targeting the highly prevalent kras g12c mutation on hla-a*11:01 in lung cancer |
| WO2024148185A2 (en) * | 2023-01-04 | 2024-07-11 | Board Of Regents, The University Of Texas System | T cell receptors targeting the highly prevalent kras g12v mutation on hla-a*11:01 in lung cancer |
| WO2024148178A2 (en) * | 2023-01-04 | 2024-07-11 | Board Of Regents, The University Of Texas System | T cell receptors targeting the highly prevalent kras g12c mutation on hla-a*03:01 in lung cancer |
| US20260216333A1 (en) * | 2023-01-04 | 2026-07-30 | Board Of Regents, The University Of Texas System | T cell receptors targeting the highly prevalent kras g12v mutation on hla-a*03:01 in lung cancer |
| WO2024215872A1 (en) * | 2023-04-11 | 2024-10-17 | The Regents Of The University Of California | Human t cell receptors targeting tumor-enhanced splicing epitopes on hla-a*02:01 for small cell carcinoma |
| EP4724458A2 (en) * | 2023-06-07 | 2026-04-15 | The Regents of the University of California | Peptide therapeutics |
| WO2025024603A2 (en) * | 2023-07-25 | 2025-01-30 | Elaine Tsiumas Kaznessis | Personalized bacterial cancer vaccines |
| AU2024315334A1 (en) * | 2023-07-28 | 2026-02-05 | Lg Chem, Ltd. | Conjugate for antigen delivery and use thereof |
| CN116970058B (zh) * | 2023-09-22 | 2023-12-15 | 成都朗谷生物科技股份有限公司 | 针对tp53基因r249s突变的肿瘤新抗原多肽及其应用 |
| GB202400424D0 (en) * | 2024-01-11 | 2024-02-28 | Cancer Research Tech Ltd | Treatment and prevention of lung cancer |
| WO2025168848A1 (en) | 2024-02-09 | 2025-08-14 | IMMUNEO Therapeutics GmbH | Hla tumor antigen polypeptides with delivering aiding capping peptides and pharmaceutical composition comprising the same |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| US6780407B1 (en) | 1989-03-08 | 2004-08-24 | Aventis Pasteur | Pox virus comprising DNA sequences encoding CEA and B7 antigen |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| EP0452457B1 (en) | 1989-11-03 | 1997-08-20 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
| US6309647B1 (en) | 1999-07-15 | 2001-10-30 | Aventis Pasteur | Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants |
| US6277558B1 (en) | 1990-11-30 | 2001-08-21 | Kansas University Medical Center | α-3 chain type IV collagen polynucleotides |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| IL106610A0 (en) | 1992-08-07 | 1993-12-08 | Cytel Corp | Hla binding peptides and their uses |
| SG49008A1 (en) | 1993-03-05 | 1998-05-18 | Cytel Corp | Hla-a2.1 binding peptides and their uses |
| US6991797B2 (en) | 1993-07-02 | 2006-01-31 | Statens Serum Institut | M. tuberculosis antigens |
| CN1135181A (zh) | 1993-09-14 | 1996-11-06 | Cytel有限公司 | 使用泛dr结合肽改变免疫应答 |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US6924128B2 (en) | 1994-12-06 | 2005-08-02 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
| US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6090393A (en) | 1996-07-03 | 2000-07-18 | Merial | Recombinant canine adenoviruses, method for making and uses thereof |
| US6156567A (en) | 1996-07-03 | 2000-12-05 | Merial | Truncated transcriptionally active cytomegalovirus promoters |
| US7255862B1 (en) | 1996-11-14 | 2007-08-14 | Connaught Technology Corporation | ALVAC/FIV constructs |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| JP2001517454A (ja) | 1997-09-19 | 2001-10-09 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組換えアデノ随伴ウイルスの産生に有用な方法および細胞株 |
| WO1999014354A1 (en) | 1997-09-19 | 1999-03-25 | The Trustees Of The University Of The Pennsylvania | Methods and vector constructs useful for production of recombinant aav |
| US6346415B1 (en) | 1997-10-21 | 2002-02-12 | Targeted Genetics Corporation | Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors |
| AU758004B2 (en) * | 1997-12-17 | 2003-03-13 | Genset S.A. | Extended cDNAs for secreted proteins |
| US6953690B1 (en) | 1998-03-20 | 2005-10-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| NO315238B1 (no) * | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
| US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
| JP2002523045A (ja) * | 1998-08-21 | 2002-07-30 | インサイト・ファーマスーティカルズ・インコーポレイテッド | ヒトｒｎａ関連タンパク質 |
| EP1135468B1 (en) | 1998-11-10 | 2010-01-06 | University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| US6893865B1 (en) | 1999-04-28 | 2005-05-17 | Targeted Genetics Corporation | Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US6793926B1 (en) | 1999-05-27 | 2004-09-21 | Genovo, Inc. | Methods for production of a recombinant adeno-associated virus |
| US6537540B1 (en) | 1999-05-28 | 2003-03-25 | Targeted Genetics Corporation | Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders |
| US6955808B2 (en) | 1999-09-24 | 2005-10-18 | Uab Research Foundation | Capsid-modified recombinant adenovirus and methods of use |
| US7115391B1 (en) | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
| CA2343602A1 (en) * | 2000-04-18 | 2001-10-18 | Genset | Est's and encoded human proteins |
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| EP2336192A1 (en) | 2004-03-11 | 2011-06-22 | Fresenius Kabi Deutschland GmbH | Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination |
| EP2573185A3 (en) | 2005-02-16 | 2013-06-05 | Lentigen Corporation | Lentiviral vectors and their use |
| UY29460A1 (es) | 2005-04-08 | 2006-11-30 | Noxxon Pharma Ag | Acidos nucleicos de union a ghrelin |
| DE602005020046D1 (de) * | 2005-09-05 | 2010-04-29 | Immatics Biotechnologies Gmbh | Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden |
| SI1760089T1 (sl) * | 2005-09-05 | 2009-12-31 | Immatics Biotechnologies Gmbh | S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku |
| TWI494319B (zh) * | 2007-02-21 | 2015-08-01 | Oncotherapy Science Inc | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| WO2008115610A1 (en) * | 2007-03-19 | 2008-09-25 | Globeimmune, Inc. | Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer |
| EP2071334A1 (en) * | 2007-12-14 | 2009-06-17 | Transmedi SA | Compositions and methods of detecting TIABS |
| US20110165566A1 (en) * | 2009-07-09 | 2011-07-07 | Wittliff James L | Methods of optimizing treatment of breast cancer |
| AU2010311332B2 (en) | 2009-10-30 | 2015-04-23 | Albumedix Ltd. | Albumin variants |
| US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
| JP2014507160A (ja) * | 2011-02-22 | 2014-03-27 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． | 循環バイオマーカー |
| WO2012121429A1 (ko) * | 2011-03-07 | 2012-09-13 | 연세대학교 산학협력단 | 암 세포 바이오 마커를 동정하는 방법 및 상기 방법으로 동정한 nmd-무관 암 세포 바이오 마커 |
| WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
| LT2714071T (lt) | 2011-05-24 | 2019-10-10 | Biontech Rna Pharmaceuticals Gmbh | Individualizuotos vakcinos nuo vėžio |
| WO2012177925A1 (en) * | 2011-06-21 | 2012-12-27 | The Board Institute, Inc. | Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| WO2013151664A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| WO2014180490A1 (en) * | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| JP7060324B2 (ja) | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
| US20190099475A1 (en) * | 2015-04-08 | 2019-04-04 | Nantomics, Llc | Cancer neoepitopes |
| CA3172682A1 (en) * | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
| JP6913032B2 (ja) * | 2015-05-20 | 2021-08-04 | ザ・ブロード・インスティテュート・インコーポレイテッド | 共通ネオ抗原 |
| JP2016028025A (ja) * | 2015-07-29 | 2016-02-25 | ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ | がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ） |
| GB201521894D0 (en) * | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| CA3012829A1 (en) * | 2016-01-27 | 2017-08-03 | Advaxis, Inc. | Personalized delivery vector-based immunotherapy and uses thereof |
| SG11201808196UA (en) * | 2016-03-31 | 2018-10-30 | Neon Therapeutics Inc | Neoantigens and methods of their use |
-
2017
- 2017-03-31 SG SG11201808196UA patent/SG11201808196UA/en unknown
- 2017-03-31 BR BR112018070183-1A patent/BR112018070183A2/pt not_active Application Discontinuation
- 2017-03-31 EP EP17776811.6A patent/EP3436048B1/en active Active
- 2017-03-31 FI FIEP17776811.6T patent/FI3436048T3/fi active
- 2017-03-31 DK DK17776811.6T patent/DK3436048T3/da active
- 2017-03-31 ES ES17776811T patent/ES3036912T3/es active Active
- 2017-03-31 PL PL17776811.6T patent/PL3436048T3/pl unknown
- 2017-03-31 LT LTEPPCT/US2017/025462T patent/LT3436048T/lt unknown
- 2017-03-31 PE PE2018001918A patent/PE20181923A1/es not_active Application Discontinuation
- 2017-03-31 KR KR1020187031742A patent/KR20180129899A/ko not_active Ceased
- 2017-03-31 CA CA3018748A patent/CA3018748A1/en active Pending
- 2017-03-31 RS RS20250878A patent/RS67172B1/sr unknown
- 2017-03-31 SI SI201731623T patent/SI3436048T1/sl unknown
- 2017-03-31 IL IL299926A patent/IL299926B2/en unknown
- 2017-03-31 WO PCT/US2017/025462 patent/WO2017173321A1/en not_active Ceased
- 2017-03-31 TW TW106111296A patent/TWI781928B/zh active
- 2017-03-31 MA MA044524A patent/MA44524A/fr unknown
- 2017-03-31 PT PT177768116T patent/PT3436048T/pt unknown
- 2017-03-31 HU HUE17776811A patent/HUE072805T2/hu unknown
- 2017-03-31 KR KR1020227041564A patent/KR20220163523A/ko not_active Ceased
- 2017-03-31 JP JP2018551996A patent/JP2019513373A/ja not_active Withdrawn
- 2017-03-31 CN CN201780034080.4A patent/CN109310739A/zh active Pending
- 2017-03-31 TW TW111138089A patent/TWI837869B/zh active
- 2017-03-31 CN CN202211177112.5A patent/CN115558030A/zh active Pending
- 2017-03-31 US US16/094,851 patent/US20190307868A1/en not_active Abandoned
- 2017-03-31 TW TW113107104A patent/TW202440616A/zh unknown
- 2017-03-31 HR HRP20251095TT patent/HRP20251095T1/hr unknown
- 2017-03-31 CR CR20180519A patent/CR20180519A/es unknown
- 2017-03-31 AU AU2017240745A patent/AU2017240745B2/en active Active
-
2018
- 2018-09-20 IL IL261880A patent/IL261880B/en unknown
- 2018-09-24 PH PH12018502047A patent/PH12018502047A1/en unknown
- 2018-09-28 MX MX2023001403A patent/MX2023001403A/es unknown
- 2018-10-29 CO CONC2018/0011668A patent/CO2018011668A2/es unknown
- 2018-10-31 EC ECSENADI201882207A patent/ECSP18082207A/es unknown
-
2021
- 2021-11-15 AU AU2021269272A patent/AU2021269272B2/en active Active
-
2022
- 2022-04-10 IL IL292094A patent/IL292094B2/en unknown
- 2022-05-31 JP JP2022088325A patent/JP7491965B2/ja active Active
-
2023
- 2023-05-02 US US18/311,158 patent/US20230414735A1/en active Pending
- 2023-05-02 US US18/311,155 patent/US20230405102A1/en not_active Abandoned
- 2023-10-05 AU AU2023241320A patent/AU2023241320B2/en active Active
-
2024
- 2024-05-16 JP JP2024080050A patent/JP2024105596A/ja active Pending
-
2025
- 2025-09-29 IL IL323656A patent/IL323656A/en unknown
- 2025-09-30 AU AU2025242131A patent/AU2025242131A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7731705B2 (ja) | Ｎａｎｔ癌ワクチン | |
| Butterfield et al. | Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations | |
| Ganesh et al. | Immunotherapy in colorectal cancer: rationale, challenges and potential | |
| Saab et al. | Insights into lung cancer immune-based biology, prevention, and treatment | |
| Bauer et al. | The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma | |
| Veatch et al. | Endogenous CD4+ T cells recognize neoantigens in lung cancer patients, including recurrent oncogenic KRAS and ERBB2 (Her2) driver mutations | |
| Moehler et al. | Immunotherapy in gastrointestinal cancer: recent results, current studies and future perspectives | |
| van der Burg et al. | Vaccines for established cancer: overcoming the challenges posed by immune evasion | |
| Khleif et al. | Cancer vaccines as enablers of immunotherapy | |
| US20210382068A1 (en) | Hla single allele lines | |
| Wang et al. | Human leukocyte antigen (HLA) and cancer immunotherapy: HLA-dependent and-independent adoptive immunotherapies | |
| KR20180085725A (ko) | 다양한 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합 | |
| TW202134430A (zh) | 腫瘤細胞疫苗 | |
| KR20180038550A (ko) | 다양한 암의 면역요법 치료에서의 사용을 위한 신규 펩티드, 펩티드의 조합 및 골격 | |
| TW201742923A (zh) | 用於新抗原表位呈現的序列安排及序列 | |
| Charlebois et al. | PolyI: C and CpG synergize with anti-ErbB2 mAb for treatment of breast tumors resistant to immune checkpoint inhibitors | |
| TW201811822A (zh) | 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架 | |
| Chatani et al. | Mutated RAS: targeting the “untargetable” with T cells | |
| IL292864A (en) | New peptides and a combination of peptides and supports for use in immunotherapy in certain types of cancer | |
| Drakes et al. | Lymph node–targeted vaccine boosting of TCR T-cell therapy enhances antitumor function and eradicates solid tumors | |
| CN112203678A (zh) | 新表位疫苗及免疫刺激组合物及方法 | |
| JP2019509265A (ja) | 二重標的化によるアデノウイルスの皮下送達 | |
| US20210172961A1 (en) | Methods for identifying rna editing-derived epitopes that elicit immune responses in cancer | |
| JP2021532122A (ja) | 癌のための個別化ワクチン | |
| TWI750644B (zh) | 用於對抗多種癌症的免疫療法的新胜肽及胜肽組合 |